Progression-Free Survival
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fan Wu, Xirong Zheng, Joseph Burnett, Madhan Masilamani, Wanying Zhang, Xiaobo Zhong, Andrea Caia, Mark Cook, Julia Piasecki, Anna Kondic, Manisha Lamba, Jian Zhou
J Clin Pharmacol 65(11) 1568-1576
Idecabtagene vicleucel (ide-cel, ABECMA) is an autologous, B-cell maturation antigen-directed, chimeric antigen receptor (CAR) T-cell therapy, which has demonstrated significantly improved progression-free survival (PFS) and overall response rate (ORR) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM). Here, we characterize cellular expansion of ide-cel in vivo and further evaluate associations between cellular expansion and clinical efficacy and safety endpoints. The exposure parameters of ide-cel were evaluated through non-compartmental analysis methods using the time course data of CAR transgene copy numbers collected from the ide-cel arm of Study KarMMa-3 (NCT03651128). Multivariable regression analyses were conducted between the exposure parameters and clinical responses to characterize relationships between cellular expansion in vivo and clinical outcomes and to evaluate potential effects of covariates on the exposure-response (E-R) relationships. There appears to be lack of a strong association between actual ide-cel dose and cellular expansion at the dose range evaluated in Study KarMMa-3. The multivariable E-R regression models suggest positive relationships between cellular expansion and clinical efficacy and safety endpoints, with higher exposure associated with longer PFS, higher ORR, and higher rates of cytokine release syndrome requiring tocilizumab or corticosteroids. The current analyses do not identify any clinically relevant covariate effects on the E-R relationships. The positive exposure-response relationships were found to be overall similar between KarMMa-3 and a previous study KarMMa. The modeling analyses, paired with clinical data, support extending the dose range from previously approved 300-460 × 106 CAR+ T cells to 300-510 × 106 CAR+ T cells for TCE RRMM patients.
1 个 Figure · 2 个 KM 面板
Figure 2 Graphical evaluation of exposure–response relationships for efficacy by quartiles of exposure metrics. (a) Progress‐free suvival by AUC0‐28D; (b) Duration of response by AUC0‐28D; (c) Overall response rate (ORR) by Cmax/Tmax (i.e., expansion rate); (d) Minimal residual disease (MRD) negative status with complete response (CR) by Cmax/Tmax) (i.e., expansion rate).
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。